Local Pharmaceutical Manufacturing for Future Sustainability
… Membership Required You must be a member to access this content.View Membership LevelsAlready a member? Log in here...
Adcock Ingram Delisting After Natco Acquisition
Adcock Ingram delisting from the JSE is confirmed for November 11. Learn about the impact of the Natco Pharma acquisition.
Adcock Ingram Takeover Gets Green Light from Shareholders
Shareholders have approved the Adcock Ingram takeover by Natco Pharma, marking a new chapter for the pharmaceutical company.
Adcock Ingram Reports Flat Profit Despite Winter Surge
Adcock Ingram reports steady annual profits as winter demand for Panado and Corenza-C drives growth in the second half.
Pharma Giants Sidelined in R15.5bn HIV Drug Tender
The recent R15.5 billion ARV tender sidelines Pharma Giants in South Africa, raising questions about local production support.
Bidvest’s Role in Adcock Ingram Takeover Bid
Learn how Bidvest's partnership with Natco Pharma impacts Adcock Ingram and shareholder rights amid a new takeover bid.
Adcock Ingram to Delist Amidst Corporate Changes
Adcock Ingram is set to delist from the JSE as Natco Pharma partners with Bidvest in a major take-private deal.
Adcock Ingram’s Lenbucod Blocked by Court Ruling
Adcock Ingram's Lenbucod blocked by court order over trademark infringement with Aspen's Mybucod. Learn more about the battle.
Adcock Ingram: A picture of resilience in a challenging market
Pharmaceutical stalwart Adcock Ingram presents a compelling case for investors seeking resilience amidst potential market turbulence. The group boasts a robust track record, with a mere 3% dip in headline earnings per share (HEPS) during the challenging Covid-impacted year of 2021. It was their worst annual performance in a decade. Since 2015, Adcock has delivered…...
Adcock Ingram’s Urizone Wins Trademark Battle
Adcock Ingram's Urizone receives legal protection as the court halts Cipla's Furizome, citing trademark infringement.